for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aldeyra Therapeutics Inc

ALDX.OQ

Latest Trade

5.17USD

Change

-0.08(-1.52%)

Volume

55,504

Today's Range

5.16

 - 

5.43

52 Week Range

4.31

 - 

13.24

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.25
Open
5.33
Volume
55,504
3M AVG Volume
4.20
Today's High
5.43
Today's Low
5.16
52 Week High
13.24
52 Week Low
4.31
Shares Out (MIL)
27.58
Market Cap (MIL)
142.58
Forward P/E
-2.36
Dividend (Yield %)
--

Latest Developments

More

Aldeyra Therapeutics Q2 Loss Per Share $0.49

Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis

Aldeyra Therapeutics Reports Q1 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Industry

Biotechnology & Drugs

Contact Info

131 Hartwell Ave Ste 320

+1.781.7614904

https://www.aldeyra.com/

Executive Leadership

Richard H. Douglas

Independent Chairman of the Board

Todd C. Brady

President, Chief Executive Officer, Director

Joshua Reed

Chief Financial Officer

Stephen Machatha

Senior Vice President, Technical Operations

David J. Clark

Chief Medical Officer

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.650

2017

-1.400

2018

-1.790

2019(E)

-2.188
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.07
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-95.61
Return on Equity (TTM)
-86.06

Latest News

Latest News

Aldeyra's eye drug meets main goal in late-stage study, shares surge

Aldeyra Therapeutics Inc said on Tuesday its drug reproxalap to treat a form of allergic reaction to the eye met the main goal in a late-stage trial, sending shares up more than 60 percent.

BRIEF-Aldeyra Therapeutics Appoints David Mcmullin As Senior Vice President, Corporate Development And Strategy

* ALDEYRA THERAPEUTICS APPOINTS DAVID MCMULLIN AS SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT AND STRATEGY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Allergic Conjunctivitis Phase 3 Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN ALLERGIC CONJUNCTIVITIS PHASE 3 CLINICAL TRIAL

BRIEF-Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs

* ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Dry Eye Disease Phase 2B Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN DRY EYE DISEASE PHASE 2B CLINICAL TRIAL Source text for Eikon: Further company coverage:

BRIEF-Aldeyra Therapeutics Posts Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data

* ALDEYRA THERAPEUTICS PRESENTS NONINFECTIOUS ANTERIOR UVEITIS PHASE 2 CLINICAL TRIAL DATA TO THE AMERICAN UVEITIS SOCIETY HELD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2017 ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Aldeyra Therapeutics reports Q3 loss per share of $0.32

* Aldeyra Therapeutics announces third quarter 2017 financial results

BRIEF-Aldeyra ‍announcesd new data for ADX-102 from Phase 2 clinical trials

* Aldeyra - announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis

BRIEF-Perceptive Advisors buys 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19

* Perceptive Advisors Llc reports purchase of 200,000 shares of Aldeyra Therapeutics Inc's common stock on Sept 19 at $7.25 per share - SEC filing

BRIEF-Aldeyra Therapeutics posts pricing of public offering of common stock

* Aldeyra Therapeutics Inc announces pricing of public offering of common stock

BRIEF-Aldeyra Therapeutics announces proposed public offering of common stock

* Aldeyra Therapeutics Inc announces proposed public offering of common stock

BRIEF-Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial

* Aldeyra Therapeutics announces positive results from dry eye disease phase 2A clinical trial Source text for Eikon: Further company coverage:

BRIEF-Aldeyra Therapeutics Q2 loss per share $0.35

* Aldeyra therapeutics announces second quarter 2017 financial results

BRIEF-Aldeyra Therapeutics expects to report results from phase 2A trial of topical ocular ADX-102 late in Q3

* Aldeyra Therapeutics-expects to report results from phase 2a trial of topical ocular ADX-102 late in Q3, 2017, not early in Q3 as stated in conf call Source text: (http://bit.ly/2rBbbkk) Further company coverage:

BRIEF-Aldeyra Therapeutics announces results from allergic conjunctivitis phase 2b clinical trial

* Aldeyra Therapeutics announces results from allergic conjunctivitis phase 2b clinical trial and plans for phase 3 clinical testing

BRIEF-Aldeyra Therapeutics enters controlled equity offering sales deal

* Aldeyra Therapeutics enters controlled equity offering sales deal under which may offer, sell,through cantor, shares with offering price up to $20 million Source text for Eikon: Further company coverage:

BRIEF-Aldeyra Therapeutics reports Q1 loss per share $0.37

* Aldeyra Therapeutics provides corporate update and announces first quarter 2017 financial results

BRIEF-Aldeyra Therapeutics says results of late stage trial expected in H2 2018

* Aldeyra therapeutics announces first patient enrolled in noninfectious anterior uveitis phase 3 clinical trial

BRIEF-Aldeyra Therapeutics receives orphan drug designation from FDA

* Aldeyra Therapeutics Inc receives orphan drug designation from the U.S. Food And Drug Administration for ADX-102 in sjögren-larsson syndrome

BRIEF-Aldeyra Therapeutics expects board size to be reduced

* Aldeyra Therapeutics - on April 3, C. Boyd Clarke, chairman of board notified co's board that he does not intend to run for re-election - sec filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up